Search results
Results from the WOW.Com Content Network
DMPA, under brand names such as Depo-Provera and Depo-SubQ Provera 104, is used in hormonal birth control as a long-lasting progestogen-only injectable contraceptive to prevent pregnancy in women. [ 38 ] [ 39 ] It is given by intramuscular or subcutaneous injection and forms a long-lasting depot , from which it is slowly released over a period ...
In the past, medrogestone was used in the treatment of endometrial cancer and in some regimens for breast cancer, and, in men, for benign prostatic hyperplasia. It still finds use in the treatment of amenorrhea [ 14 ] and as the progestin component in certain forms of menopausal hormone therapy .
Progestogens that have been studied for potential use as POICs but were never marketed as such include the progesterone derivatives algestone acetophenide (dihydroxyprogesterone acetophenide) (100 mg/month), chlormadinone acetate (250 mg/3 months), hydroxyprogesterone caproate (250–500 mg/month), gestonorone caproate (2.5–200 mg/1–2 ...
1–5 mg/day Dutasteride: Avodart: 5αR inhibitor: Oral: 0.25–0.5 mg/day Progesterone: Prometrium [c] Progestogen: Oral: 100–400 mg/day Medroxyprogesterone acetate: Provera: Progestogen: Oral: 2.5–40 mg/day Depo-Provera: Progestogen: IM: 150 mg every 3 mos: Depo-SubQ Provera 104: Progestogen: SC: 104 mg every 3 mos Hydroxyprogesterone ...
Compared to MPA, medroxyprogesterone is over two orders of magnitude less potent as a progestogen. [8] Medroxyprogesterone is also notable in that it is a minor metabolite of MPA. [9] In addition to its progestagenic activity, medroxyprogesterone is a weak antiandrogen in vitro on human androgen receptor. [10]
With 20 years of use, breast cancer incidence is about 1.5-fold higher with estrogen alone and about 2.5-fold higher with estrogen plus progestogen therapy relative to non-use. [151] The increase in breast cancer risk with estrogen and progestogen therapy was shown to be causal with conjugated estrogens plus medroxyprogesterone acetate in the ...
Estradiol cypionate/medroxyprogesterone acetate (EC/MPA), sold under the brand name Cyclofem among others, is a form of combined injectable birth control. [2] It contains estradiol cypionate (EC), an estrogen, and medroxyprogesterone acetate (MPA), a progestin. [2] It is recommended for short-term use and is given once a month by injection into ...
Combined oral contraception decreases total testosterone levels by approximately 0.5 nmol/L, free testosterone by approximately 60%, and increases the amount of sex hormone binding globulin (SHBG) by approximately 100 nmol/L. Contraceptives containing second generation progestins and/or estrogen doses of around 20 –25 mg EE were found to have ...